scispace - formally typeset
K

Kenneth W. Hill

Researcher at Agilent Technologies

Publications -  5
Citations -  77

Kenneth W. Hill is an academic researcher from Agilent Technologies. The author has contributed to research in topics: Derivative (chemistry) & Aryl. The author has an hindex of 3, co-authored 5 publications receiving 73 citations.

Papers
More filters
Journal ArticleDOI

Streamlined Process for the Chemical Synthesis of RNA Using 2′-O-Thionocarbamate-Protected Nucleoside Phosphoramidites in the Solid Phase

TL;DR: An improved method was developed utilizing a streamlined method for the preparation of phosphoramidite monomers and a single-step deprotection of the resulting oligoribonucleotide product using 1,2-diamines under anhydrous conditions and it was demonstrated that the chemical synthesis of RNA can be as simple and robust as thechemical synthesis of DNA.
Patent

Retro diels alder reaction as a cleavable linker in dna/rna applications

TL;DR: In this article, an approach for reversibly conjugating an oligonucleotide was proposed, which includes obtaining an oligoneucleotide labeled with a diene moiety and a target entity labeled with dienophile moiety, and heating the oligoneuclidean to a solution at a first temperature to effect Diels Alder reaction to produce a conjugate.
Patent

Compositions and Methods for Conjugating Oligonucleotides

TL;DR: An oligonucleotide derivative having the structure of formula (A) and methods for preparing the oligon nucleotide derivative are disclosed in this paper, where an amino or thiol group is added to the first oligonotide derivative.
Patent

Preparation of long synthetic oligonucleotides by squarate conjugation chemistry

TL;DR: In this article, the authors provide methods of conjugating oligonucleotides using a squarate reagent to produce an activated first oligonotide, and binding the first and second oligon nucleosides to a splint splint.
Patent

Method for conjugating oligonucleotides

TL;DR: In this paper, an oligonucleotide derivative having the structure of formula (A) and methods for preparing the oligon nucleotide derivative are disclosed, wherein R3 is a first oligonotide; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl, a polyethylene glycol, a peptide, a protein, polysaccharide, and a second oligoneotide.